Objective: To investigate the role of the HS1,2 enhancer polymorphisms as a novel candidate marker for rheumatoid arthritis (RA) and to define the possible association with autoantibody positivity and clinical outcome.
Methods: Genomic DNA was obtained from two cohorts of RA patients (100 patients with an early RA-ERA and 114 patients with long standing RA-LSRA) and from 248 gender matched controls from the same geographic area. Clinical and immunological characteristics were recorded for all the patients.
Results: The percentage of the 2/2 genotype was higher in ERA patients (27.0%), as well as in LSRA patients (34.2%), than in the control group (14.9%) (ERA OR=2.11, 95%CIs: [1.20-3.70] vs controls, LSRA OR=2.97, C.I.95%: [1.76-5.00] vs controls). A lower representation of allele*3 was present in ERA patients (2.0%) when compared to the controls (6.0%; OR=0.32, C.I.95%: [0.11-0.91]). No significant associations were found between polymorphisms and autoantibodies positivity (Anti-CCP, IgM-RF and IgA-RF).
Conclusion: The HS1,2A allele*2 associates with RA (either in ERA as well as in LSRA).
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.